Dr Afshin Dowlati discusses a new way to predict effectiveness of chemotherapy

Doctors often have trouble knowing who might respond to certain cancer treatments. “We kind of give chemotherapy and wish for a good result,” says Dr. Afshin Dowlati of CWRUmedicine’s Hematology Oncology. That could change. Dowlati led a study that revealed lung cancer patients with low levels of a molecule that controls cellular interaction have twice the chance of responding to chemotherapy than those with high levels. Those levels can also predict how likely a patient is to live a year after diagnosis. The difference could help patients decide whether to try chemotherapy, drugs or pursue alternative therapies, Dowlati says.

Read more at Cleveland Magazine :: http://tiny.cc/ssiZv

Tags: Afshin Dowlati, best cancer care, cancer, cancer hospital, cancer patient, cancer treatment, case medical center, case western reserve, case western reserve department of medicine, case western reserve school of medicine, case western reserve university, chemotherapy, cwrumedicine, division of hem onc, division of Hematology/Oncology, hematology oncology, hemonc, ireland cancer center, uh cmc, university hospitals, university hospitals case medical center